Adjuvant endocrine therapy in pre- and perimenopausal women with breast cancer: practice guidelines

17 92 Introduction Breast cancer is a common disease. In 2012 (latest available fi gures), 10,531 female breast cancer cases were diagnosed in Belgium. Among these, 2,079 were diagnosed before the age of 50 and 1,243 additional cases were diagnosed between the ages of 50 and 54. The exact number of premenopausal patients with oestrogen receptor positive early invasive breast cancer is unfortunately not known, but given these fi gures, we estimate that in Belgium, every year, between 2,000 and 3,000 women are diagnosed in this setting.

[1]  S. Loibl,et al.  Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Montemurro,et al.  Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.

[3]  F. Cardoso,et al.  Breast Cancer Under Age 40: a Different Approach , 2015, Current Treatment Options in Oncology.

[4]  J. Forbes,et al.  Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. , 2015, The New England journal of medicine.

[5]  R. Greil,et al.  Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Martino,et al.  Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[8]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Earl,et al.  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[11]  O. Pagani,et al.  Pregnancy after Breast Cancer: Myths and Facts , 2012, Breast Care.

[12]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[14]  M. Piccart,et al.  Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.